- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00355342
Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
27 mars 2018 uppdaterad av: GlaxoSmithKline
A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Twice Daily Via DISKUS® Inhaler Versus Salmeterol 50mcg Twice Daily Via DISKUS® Inhaler on Bone Mineral Density in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This study will last up to 3 years.
You will visit the clinic up to 14 times.
Certain visits will include lung function tests and scans of your bones.
The purpose of this study is to determine the effect of the steroid component of an inhaled product on bone mineral density in patients with Chronic Obstructive Pulmonary Disease (COPD).
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
186
Fas
- Fas 4
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
California
-
Berkeley, California, Förenta staterna, 94705
- GSK Investigational Site
-
Fullerton, California, Förenta staterna, 92835
- GSK Investigational Site
-
Rancho Mirage, California, Förenta staterna, 92270
- GSK Investigational Site
-
San Diego, California, Förenta staterna, 92103
- GSK Investigational Site
-
Walnut Creek, California, Förenta staterna, 94598
- GSK Investigational Site
-
-
Colorado
-
Fort Collins, Colorado, Förenta staterna, 80528
- GSK Investigational Site
-
Wheat Ridge, Colorado, Förenta staterna, 80033
- GSK Investigational Site
-
-
Connecticut
-
Hartford, Connecticut, Förenta staterna, 06105
- GSK Investigational Site
-
-
Florida
-
Fort Lauderdale, Florida, Förenta staterna, 33316
- GSK Investigational Site
-
Jacksonville, Florida, Förenta staterna, 32205
- GSK Investigational Site
-
Sarasota, Florida, Förenta staterna, 34239
- GSK Investigational Site
-
Tamarac, Florida, Förenta staterna, 33321
- GSK Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30342
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60612
- GSK Investigational Site
-
North Chicago, Illinois, Förenta staterna, 60064
- GSK Investigational Site
-
-
Kansas
-
Wichita, Kansas, Förenta staterna, 67207
- GSK Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02135
- GSK Investigational Site
-
-
Michigan
-
Cadillac, Michigan, Förenta staterna, 49601
- GSK Investigational Site
-
-
Missouri
-
Saint Charles, Missouri, Förenta staterna, 63301
- GSK Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68124
- GSK Investigational Site
-
-
New York
-
Bronxville, New York, Förenta staterna, 10708
- GSK Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, Förenta staterna, 28207
- GSK Investigational Site
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97213
- GSK Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29406-7108
- GSK Investigational Site
-
Greer, South Carolina, Förenta staterna, 29651
- GSK Investigational Site
-
Simpsonville, South Carolina, Förenta staterna, 29681
- GSK Investigational Site
-
Spartanburg, South Carolina, Förenta staterna, 29303
- GSK Investigational Site
-
-
Tennessee
-
Kingsport, Tennessee, Förenta staterna, 37660
- GSK Investigational Site
-
Milan, Tennessee, Förenta staterna, 38372
- GSK Investigational Site
-
-
Texas
-
Corsicana, Texas, Förenta staterna, 75110
- GSK Investigational Site
-
San Antonio, Texas, Förenta staterna, 78217
- GSK Investigational Site
-
San Antonio, Texas, Förenta staterna, 78205
- GSK Investigational Site
-
-
Virginia
-
Richmond, Virginia, Förenta staterna, 23249
- GSK Investigational Site
-
Richmond, Virginia, Förenta staterna, 23225
- GSK Investigational Site
-
-
Washington
-
Bellingham, Washington, Förenta staterna, 98226
- GSK Investigational Site
-
Spokane, Washington, Förenta staterna, 99204
- GSK Investigational Site
-
Spokane, Washington, Förenta staterna, 99202
- GSK Investigational Site
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
40 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion criteria:
- Established clinical history of COPD.
- Baseline FEV1 <70% predicted normal, and FEV1/FVC ratio of less than 70%.
- Smoking history of at least 10 pack-years, where both current and former smokers will be eligible.
- Must have at least one native, evaluable hip.
Exclusion criteria:
- History of or evidence for metabolic bone diseases other than osteoporosis or osteopenia.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Salmeterol 50 mcg BID
Participants randomized to this arm received salmeterol 50 microgram (mcg), formulated with lactose via the DISKUS™ inhaler one inhalation twice daily (BID) one inhalation in the morning and one inhalation in the evening for 156 Weeks.
Each DISKUS contained 60 doses of study medication.
Participant were provided with albuterol/salbutamol as relief medication.
DISCUS is registered trademark product of GlaxoSmithKline.
|
Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
Andra namn:
Each participant received study medication via the DISKUS, for one of two possible treatment groups.
Each DISKUS contained 60 doses of study medication.
Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
|
|
Experimentell: Fluticasone Propionate/Salmeterol 250/50 mcg BID
Participants randomized to this arm received Fluticasone propionate/salmeterol combination product 250/50 mcg, formulated with lactose via the DISKUS inhaler one inhalation BID, one inhalation in the morning and one inhalation in the evening for 156 Weeks.
Each DISKUS contained 60 doses of study medication.
Participant were provided with albuterol/salbutamol as relief medication.
|
Each participant received study medication via the DISKUS, for one of two possible treatment groups.
Each DISKUS contained 60 doses of study medication.
Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
Fluticasone propionate/salmeterol xinafoate combination product 250/50mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine L1-L4
Tidsram: Baseline and Week 26, 52, 78, 104, 130, and 156
|
BMD, a measure of bone density, reflecting the strength of bones as represented by calcium content.
The BMD test detects osteopenia (mild bone loss) and osteoporosis (more severe bone loss, which may cause symptoms).
BMD at the lumber spine (L1-L4) was measured via dual energy x-ray absorptiometry (DEXA) (using DEXA equipment) scans at Baseline and every 26 weeks during the study.
Acceptable DEXA measurements must be conducted prior to the first dose of randomized study medication.
Baseline was defined as the collections taken on Day 1 of treatment period.
Change from Baseline was calculated by subtracting the Baseline value from indicated time point value.
|
Baseline and Week 26, 52, 78, 104, 130, and 156
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percent Change From Baseline in BMD at the Total Hip
Tidsram: Baseline and Week 26, 52, 78, 104, 130, and 156
|
BMD, a measure of bone density, reflecting the strength of bones as represented by calcium content.
The BMD test detects osteopenia (mild bone loss) and osteoporosis (more severe bone loss, which may cause symptoms).BMD at the total hip was measured via dual energy x-ray absorptiometry (DEXA) (using DEXA equipment) scans at Baseline and every 26 weeks during the study.
Acceptable DEXA measurements must be conducted prior to the first dose of randomized study medication.
Baseline was defined as the collections taken on day 1 of treatment period.
Change from Baseline was calculated by subtracting the Baseline value from indicated time point value.
|
Baseline and Week 26, 52, 78, 104, 130, and 156
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Allmänna publikationer
- This study has not been published in the scientific literature.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
28 april 2004
Primärt slutförande (Faktisk)
6 september 2007
Avslutad studie (Faktisk)
6 september 2007
Studieregistreringsdatum
Först inskickad
19 juli 2006
Först inskickad som uppfyllde QC-kriterierna
19 juli 2006
Första postat (Uppskatta)
21 juli 2006
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
2 juli 2018
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
27 mars 2018
Senast verifierad
1 mars 2018
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Luftvägssjukdomar
- Lungsjukdomar
- Lungsjukdomar, obstruktiv
- Lungsjukdom, kronisk obstruktiv
- Läkemedels fysiologiska effekter
- Adrenerga medel
- Neurotransmittormedel
- Molekylära mekanismer för farmakologisk verkan
- Autonoma agenter
- Agenter från det perifera nervsystemet
- Antiinflammatoriska medel
- Adrenerga agonister
- Dermatologiska medel
- Bronkdilaterande medel
- Anti-astmatiska medel
- Andningsorgan
- Anti-allergiska medel
- Adrenerga beta-2-receptoragonister
- Adrenerga beta-agonister
- Flutikason
- Xhance
- Salmeterol Xinafoate
Andra studie-ID-nummer
- SCO40041
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
JA
IPD-planbeskrivning
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Studiedata/dokument
-
Statistisk analysplan
Informationsidentifierare: SCO40041Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Informerat samtycke
Informationsidentifierare: SCO40041Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Datauppsättningsspecifikation
Informationsidentifierare: SCO40041Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Studieprotokoll
Informationsidentifierare: SCO40041Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Datauppsättning för individuella deltagare
Informationsidentifierare: SCO40041Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Annoterad fallrapportformulär
Informationsidentifierare: SCO40041Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinisk studierapport
Informationsidentifierare: SCO40041Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .